Merck-Eisai Partnered Two Keytruda/Lenvima Combo Trials Flunk In Certain Types Of Lung Cancer
Portfolio Pulse from Vandana Singh
Merck & Co Inc and Eisai Co Ltd have announced that two Phase 3 trials, LEAP-006 and LEAP-008, evaluating Keytuda plus Lenvima in patients with certain types of metastatic non-small cell lung cancer, did not meet their primary endpoints. The safety profiles of the treatment regimens were consistent with previous studies. Keytruda plus Lenvima is approved in the U.S., the EU, Japan, and other countries for advanced renal cell carcinoma and certain types of advanced endometrial carcinoma.
September 22, 2023 | 2:21 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Eisai's partnership with Merck on the two Phase 3 trials for Keytruda plus Lenvima did not meet their primary endpoints, which could negatively impact investor sentiment.
The failure of the trials could lead to a decrease in investor confidence in Eisai, potentially leading to a decrease in the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
NEGATIVE IMPACT
Eisai's partnership with Merck on the two Phase 3 trials for Keytruda plus Lenvima did not meet their primary endpoints, which could negatively impact investor sentiment.
The failure of the trials could lead to a decrease in investor confidence in Eisai, potentially leading to a decrease in the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
NEGATIVE IMPACT
Merck's two Phase 3 trials for Keytruda plus Lenvima did not meet their primary endpoints, which could negatively impact investor sentiment.
The failure of the trials could lead to a decrease in investor confidence in Merck, potentially leading to a decrease in the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100